Abstract
Children with fibrolamellar hepatocarcinoma (FHC) and conventional hepatocellular carcinoma (HCC) have similar long-term outcomes despite previous evidence suggesting otherwise, according to a multinational group of researchers. Daniel Aronson (Emma Childrens Hospital, Amsterdam, Netherlands) and colleagues centrally reviewed the records of 65 children previously enrolled in the SIOPEL2 and SIOPEL3 trials. 24 children had FHC compared with 41 with HCC. Although differences were noted in patient demographics, treatments used, and early response, overall survival plateaued at about 20–25% at 2·5 years for HCC and at 4 years for FHC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
